Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth stories—and it’s not just hype. Powered by blockbuster drugs for diabetes and weight loss, a deep pipeline of next-generation treatments, and aggressive investment in future capacity, Lilly is rewriting what long-term success looks like in Big Pharma.
For everyday investors looking for strong growth potential in a defensive sector, Eli Lilly is a name worth watching, and possibly owning.
